‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of$130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of$71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to$410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening dis ...